GlassScriptPhysician profile
Ramani M Reddy
NPI 1417955154
$1,991.85
in general payments reported to CMS, 2019-2025
25 companies · $99.12 in 2025
The $99.12 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.21 · 2020: $72.23 · 2022: $281 · 2023: $786 · 2024: $740 · 2025: $99.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,624.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $503.60 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Astellas Pharma US INC | $165.59 | 2022-2025 | Veozah |
| Amgen INC. | $163.64 | 2023-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $152.63 | 2022-2024 | |
| Dexcom, INC. | $131.15 | 2022-2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $130.09 | 2023-2024 | |
| Pfizer INC. | $104.24 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $68.03 | 2023-2024 | Rexulti |
| Glaxosmithkline, LLC. | $63.71 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $62.26 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $59.66 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $55.17 | 2020-2024 | Mounjaro, Trulicity, Zepbound |
| Abbott Laboratories | $49.57 | 2023-2024 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $40.12 | 2023 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $36.39 | 2023 | Camzyos |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $31.94 | 2020 | |
| Sumitomo Pharma America, INC. | $28.69 | 2023-2024 | Gemtesa |
| Medtronic, INC. | $26.76 | 2025 | Intellis Adaptivestim |
| Daiichi Sankyo INC. | $21.42 | 2023 | Injectafer |
| Merck Sharp & Dohme LLC | $19.68 | 2023 | Verquvo, Belsomra |
| Phathom Pharmaceuticals, INC. | $18.54 | 2024 | Voquezna |
| W. L. Gore & Associates, INC. | $16.32 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.05 | 2024 | Jardiance |
| Azurity Pharmaceuticals, INC. | $13.86 | 2023 | Edarbyclor |
| Amarin Pharma, INC. | $13.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramani Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.